LSE:RENE (ReNeuron Group)

About RENE

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and US. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.